The discovery of epigenetic mechanism of BRCA1/2 germinal mutation and the association of this mutation with ovarian cancer in 5-10% of the cases, led to the therapeutic concept of "synthetic lethality" [42]. This evidence concerns the gene BRCA1 and ovarian cancer.